Bell Media unveiled its 2025/26 lineup of English and French-language original content today, featuring a total of 116 titles of premium original content and documentaries. The exciting slate ...

Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced the first patient has been dosed in its Phase 2 WISPer ...

Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. Eli Lilly is ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly recently announced encouraging Phase 1 results for its ovarian cancer treatment using a folate receptor alpha ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Rhetty for History explored some of the popular brands and products that started out under different names that didn't work ...

When Chuck Lorre and Bill Prady were coming up with that idea that would become the long-running sitcom The Big Bang Theory, ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...